Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Update on the effects and safety of INS-50589

Aug. 17, 2005

New data on the pharmacokinetics and pharmacodynamics of dabigatran

Aug. 17, 2005

BMS-593214: a novel inhibitor of FVIIa

Aug. 16, 2005

Update on TGN-255 in the prevention of thrombosis

Aug. 16, 2005

Further investigation of orally active FXa inhibitor razaxaban

Aug. 11, 2005

Promising results with oral FXa inhibitor BAY-59-7939 reported at ISTH meeting

Aug. 11, 2005

Tanogitran demonstrates a superior efficacy profile than melagatran in vitro

Aug. 10, 2005

Preclinical and clinical study data presented on novel antiplatelet agent CS-747

Aug. 10, 2005

Pharmacokinetics/pharmacodynamics of oral direct thrombin inhibitor TGN-167

Aug. 10, 2005

Octaparin exerts antithrombotic effect without impairment of hemostasis in animal models

Aug. 10, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...